AstraZeneca Reports Results of Roxadustat in Global Phase III Programme for Cardiovascular Safety in Patients with Chronic Kidney Disease
Shots:
- The P-III global programme involves assessing of Roxadustat vs PBO & epoetin alfa in 9-000+ patients with anemia + CKD not on dialysis (NDD) - dialysis-dependent (DD)- ID respectively
- Pooled analyses results: MACE/MACE+ in NDD & DD patients- clinically no difference; MACE/MACE+ in ID patients shows better results
- Roxadustat is hypoxia-inducible-factor prolyl hydroxylase inhibitor- evaluated under the collaboration of AstraZeneca- FibroGen and Astellas with its expected FDA’s regulatory submission in H2’19
Click here to read full press release/ article
Ref: AstraZeneca | Image: AstraZeneca
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com